galantamine + iot

The name **galantamine + iot** appears to be a misidentification of **Gal HCL + IOT**, a combination therapy in development by **LTN Pharmaceuticals**. The "Gal" component refers to **galeterone hydrochloride** (also known as TOK-001 or VN/124-1), a multi-targeted small molecule designed for the treatment of prostate cancer. Galeterone acts through a triple mechanism: it inhibits the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), antagonizes the androgen receptor (AR), and induces AR degradation (acting as a selective androgen receptor degrader, or SARD). The "IOT" component is a generic placeholder for an undisclosed **immuno-oncology therapy**. According to LTN Pharmaceuticals' pipeline, this combination is currently in **Phase 1** clinical development for **prostate cancer**, specifically targeting castration-resistant forms. Galantamine itself is an unrelated acetylcholinesterase inhibitor used for Alzheimer's disease and is not part of this oncology program.

Other names

galeterone + iotTOK-001 + IOTVN/124-1 + IOTgaleterone hydrochloride + iot